Harry L Brielmann, 65196 Turtle Bay Dr, Branford, CT 06405
Harry Brielmann Phones & Addresses
196 Turtle Bay Dr, Branford, CT 06405
Goldens Bridge, NY
Westbrook, CT
14 Elm St, Guilford, CT 06437 203-4570374
Canton, MI
Middletown, CT
Mentions for Harry L Brielmann
Publications & IP owners
Us Patents
Spiro[Isobenzofuran-1,4²-Piperidin]-3-Ones And 3H-Spiroisobenzofuran-1,4²-Piperidines
US Patent:
6566367, May 20, 2003
Filed:
Dec 11, 2001
Appl. No.:
10/013846
Inventors:
Rajagopal Bakthavatchalam - Branford CT
Charles A. Blum - Westbrook CT
Harry L. Brielmann - Guilford CT
James William Darrow - Wallingford CT
Alan Hutchison - Madison CT
Jennifer Tran - Guilford CT
Xiaozhang Zheng - Branford CT
Richard Louis Elliott - East Lyme CT
Marlys Hammond - Salem CT
Charles A. Blum - Westbrook CT
Harry L. Brielmann - Guilford CT
James William Darrow - Wallingford CT
Alan Hutchison - Madison CT
Jennifer Tran - Guilford CT
Xiaozhang Zheng - Branford CT
Richard Louis Elliott - East Lyme CT
Marlys Hammond - Salem CT
Assignee:
Pfizer Inc. - New York NY
Neurogen Corporation - Branford CT
Neurogen Corporation - Branford CT
International Classification:
C07D47110
US Classification:
514278, 546 17, 546199
Abstract:
Substituted spiro[isobenzofuran-1,4â-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4â-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e. g. , eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.
Substituted 2-Cyclohexyl-4-Phenyl-1H-Imidazole Derivatives
US Patent:
7034034, Apr 25, 2006
Filed:
Oct 21, 2002
Appl. No.:
10/274851
Inventors:
Charles A. Blum - Westbrook CT, US
Harry L. Brielmann - Guilford CT, US
Stephane De Lombaert - Madison CT, US
Xiaozhang Zheng - Branford CT, US
Harry L. Brielmann - Guilford CT, US
Stephane De Lombaert - Madison CT, US
Xiaozhang Zheng - Branford CT, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
A61K 31/4164
A61K 31/4178
C07D 233/64
C07D 401/12
A61K 31/4178
C07D 233/64
C07D 401/12
US Classification:
514275, 514341, 514381, 514393, 514396, 544331, 5462727, 5483451, 548250, 5483021
Abstract:
Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives capable of modulating NPY5 receptor activity, are provided. Such compounds may be used to modulate NPY binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e. g. , eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.
Substituted Quinazolin-4-Ylamine Analogues
US Patent:
7074799, Jul 11, 2006
Filed:
Jan 17, 2003
Appl. No.:
10/347210
Inventors:
Rajagopal Bakthavatchalam - Madison CT, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Timothy M. Caldwell - Branford CT, US
Stephane De Lombaert - Madison CT, US
Kevin J. Hodgetts - Killingworth CT, US
Xiaozhang Zheng - Branford CT, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Timothy M. Caldwell - Branford CT, US
Stephane De Lombaert - Madison CT, US
Kevin J. Hodgetts - Killingworth CT, US
Xiaozhang Zheng - Branford CT, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
C07D 403/12
C07D 403/14
A61K 31/519
A61P 3/04
C07D 403/14
A61K 31/519
A61P 3/04
US Classification:
51426411, 544279, 5442662, 544248
Abstract:
Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
Substituted Quinazolin-4-Ylamine Analogues
US Patent:
7304059, Dec 4, 2007
Filed:
Feb 1, 2006
Appl. No.:
11/345926
Inventors:
Rajagopal Bakthavatchalam - Madison CT, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Timothy M. Caldwell - Guilford CT, US
Stéphane De Lombaert - Madison CT, US
Kevin J. Hodgetts - Killingworth CT, US
Xiaozhang Zheng - Branford CT, US
Taeyoung Yoon - Newton MA, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Timothy M. Caldwell - Guilford CT, US
Stéphane De Lombaert - Madison CT, US
Kevin J. Hodgetts - Killingworth CT, US
Xiaozhang Zheng - Branford CT, US
Taeyoung Yoon - Newton MA, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
C07D 403/12
C07D 403/14
A61K 31/517
C07D 403/14
A61K 31/517
US Classification:
5142338, 5142662, 51426621, 51426622, 51426623, 51426624, 5142664, 544116, 544284, 544292
Abstract:
Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
Substituted (7-Pyridyl-4-Phenylamino-Quinazolin-2-Yl)-Methanol Analogues
US Patent:
7329664, Feb 12, 2008
Filed:
Jul 16, 2004
Appl. No.:
10/892741
Inventors:
Rajagopal Bakthavatchalam - Madison CT, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Stéphane De Lombaert - Madison CT, US
Xiaozhang Zheng - Branford CT, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Stéphane De Lombaert - Madison CT, US
Xiaozhang Zheng - Branford CT, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
A61K 31/517
A61K 31/519
C07D 401/04
C07D 405/14
C07D 487/04
A61K 31/519
C07D 401/04
C07D 405/14
C07D 487/04
US Classification:
51426621, 51426411, 544279, 544284
Abstract:
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
Carboxylic Acid, Phosphate Or Phosphonate Substituted Quinazolin-4-Ylamine Analogues As Capsaicin Receptor Modulators
US Patent:
7432275, Oct 7, 2008
Filed:
Dec 12, 2003
Appl. No.:
10/539031
Inventors:
Rajagopal Bakthavatchalam - Madison CT, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Timothy M. Caldwell - Guilford CT, US
Stéphane DeLombaert - Madison CT, US
Kevin J. Hodgetts - Killingworth CT, US
Xiaozhang Zheng - Branford CT, US
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Timothy M. Caldwell - Guilford CT, US
Stéphane DeLombaert - Madison CT, US
Kevin J. Hodgetts - Killingworth CT, US
Xiaozhang Zheng - Branford CT, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
A01N 43/54
A61K 31/517
C07D 239/72
A61K 31/517
C07D 239/72
US Classification:
5142664, 544293
Abstract:
Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
Substituted Biaryl Piperazinyl-Pyridine Analogues
US Patent:
7662830, Feb 16, 2010
Filed:
Aug 13, 2005
Appl. No.:
11/204202
Inventors:
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Bertrand L. Chenard - Waterford CT, US
Xiaozhang Zheng - Branford CT, US
Harry Brielmann - Guilford CT, US
Bertrand L. Chenard - Waterford CT, US
Xiaozhang Zheng - Branford CT, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
C07D 401/14
C07D 403/14
A61K 31/506
A61P 19/02
A61K 31/53
C07D 403/14
A61K 31/506
A61P 19/02
A61K 31/53
US Classification:
514275, 544326, 544328, 544330, 544331, 544194, 514246
Abstract:
Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula:.
Substituted Biaryl Piperazinyl-Pyridine Analogues
US Patent:
8334382, Dec 18, 2012
Filed:
Feb 15, 2010
Appl. No.:
12/705964
Inventors:
Charles A. Blum - Westbrook CT, US
Harry Brielmann - Guilford CT, US
Bertrand L. Chenard - Waterford CT, US
Xiaozhang Zheng - Branford CT, US
Harry Brielmann - Guilford CT, US
Bertrand L. Chenard - Waterford CT, US
Xiaozhang Zheng - Branford CT, US
Assignee:
Neurogen Corporation - Branford CT
International Classification:
C07D 403/14
C07D 401/14
A61K 31/506
A61K 31/53
A61P 19/02
C07D 401/14
A61K 31/506
A61K 31/53
A61P 19/02
US Classification:
544326, 544328, 544330, 544331, 544194, 514275, 514246
Abstract:
Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula:.
Isbn (Books And Publications)
Natural Products From Plants
Author:
Harry L. Brielmann
ISBN #:
0849329760
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.